Conference call scheduled for 4:30 p.m. Eastern TimeWALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 19, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2025. ...

Ardelyx (ARDX) announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 12,539,299 titled “Oral Formulations of Tenapanor” with an expiration date of November 26, 2042. The patent relates to the formulation of tenapanor and covers the commercial formulations of Isbrela and Xphozah. The patent will be submitted to the Food and Drug Administration for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations for both products. Published first on T ...

Core Insights - Ardelyx, Inc. has been granted a new patent for IBSRELA and XPHOZAH, which will expire on November 26, 2042, covering the formulation of tenapanor [1][2] Company Overview - Ardelyx is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs [1][15] - The company has two commercial products approved in the U.S.: IBSRELA and XPHOZAH [15] Product Information IBSRELA (tenapanor) - IBSRELA is an oral formulation that acts as a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), reducing sodium absorption and retaining luminal water content, which helps in softening stool consistency [3][11] - It has been shown to alleviate abdominal pain by decreasing visceral hypersensitivity and intestinal permeability in animal models [3] XPHOZAH (tenapanor) - XPHOZAH is a phosphate absorption inhibitor that works locally in the gut to reduce phosphate absorption through the paracellular pathway [4][14] - It is administered as a single tablet taken twice daily, with diarrhea being the most common side effect reported in clinical trials [4][13] Patent and Intellectual Property - The newly granted patent reflects a Patent Term Adjustment due to delays from the USPTO, extending protections for Ardelyx's portfolio of medicines [2] - The patent will be submitted for listing in the FDA's Orange Book for both IBSRELA and XPHOZAH [1]

Company Overview - Ardelyx, Inc. (NASDAQ: ARDX) is a biopharmaceutical company focused on developing and commercializing first-in-class gastrointestinal and cardiorenal therapies [3] Financial Updates - TD Cowen raised its price target on ARDX to $13 from $10 while maintaining a Buy rating, following an update to the firm's financial model ahead of ARDX's fourth-quarter results [1] - Jefferies also raised its price target on Ardelyx, Inc. to $15 from $8 and maintained a Buy rating, highlighting the company as one of the most underrated biotech launches [2] Product and Market Potential - Ardelyx's lead product, tenapanor, treats irritable bowel syndrome with constipation (IBS-C) and chronic kidney disease-related conditions [3] - Peak sales for tenapanor are projected at $1.5–$2 billion by 2035, with additional upside if the new 2041 formulation patent proves defendable [2]

​Ardelyx, Inc. (NASDAQ:ARDX) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 27, Dennis Ding from Jefferies reiterated a Buy rating on the stock and raised the price target from $8 to $15. Earlier, on January 9, Julian Harrison from BTIG reiterated a Buy rating on Ardelyx, Inc. (NASDAQ:ARDX) and raised the price target from $14 to $17. ​Analysts from BITG noted that the positive sentiment is based on the company’s Ibsrela revenue, which grew 73% year-over-year to $274 million in f ...

WALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the first patient has been dosed in ACCEL (ten-03-301), a Phase 3 clinical trial designed to assess the safety and efficacy of IBSRELA® (tenapanor) for the treatment of chronic idiopathic constipation (CIC) in adults. ACCEL is a multicenter, ...

Investors might want to bet on Ardelyx (ARDX) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The powe ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.ONeil Trader is a former stockbroker turned full-time independent investor. He focuses on ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.ONeil Trader is a former stockbroker turned full-time independent investor. He focuses on ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Considering buying LRCX stock? Here’s what analysts think: Photo via Shutterstock ...